Targeting the hallmarks of cancer: the effects of silibinin on proliferation, cell death, angiogenesis, and migration in colorectal cancer.
| Autor: | Sameri S; Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran., Mohammadi C; Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran., Mehrabani M; Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran., Najafi R; Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. re.najafi@umsha.ac.ir. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMC complementary medicine and therapies [BMC Complement Med Ther] 2021 May 31; Vol. 21 (1), pp. 160. Date of Electronic Publication: 2021 May 31. |
| DOI: | 10.1186/s12906-021-03330-1 |
| Abstrakt: | Background: Silibinin, as a chemopreventive agent, has shown anti-cancer efficacy against different types of cancers. In the present study, we investigated the anti-cancer activities of silibinin on CT26 mouse colon cell line. Methods: CT26 cells were treated with different concentrations of silibinin. To examine the cytotoxic effect of silibinin on proliferation, apoptosis, autophagy, angiogenesis, and migration, MTT, colony-forming assay, Annexin V/PI flow cytometry, RT-qPCR, and Scratch assay were used. Results: Silibinin was found to significantly reduce CT26 cells survival. Furthermore, silibinin strongly induced apoptosis and autophagy by up-regulating the expression of Bax, Caspase-3, Atg5, Atg7 and BECN1 and down-regulating Bcl-2. Silibinin considerably down-regulated the expression of COX-2, HIF-1α, VEGF, Ang-2, and Ang-4 as well as the expression of MMP-2, MMP-9, CCR-2 and CXCR-4. Conclusions: The present study revealed that silibinin shows anticancer activities by targeting proliferation, cell survival, angiogenesis, and migration of CT26 cells. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|